Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de viabilidad inicial de válvula Autus

15 de octubre de 2026 actualizado por: Edwards Lifesciences

Estudio de factibilidad temprana de la válvula de tamaño ajustable Autus para el reemplazo quirúrgico de la válvula pulmonar

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

Descripción general del estudio

Estado

Activo, no reclutando

Tipo de estudio

Intervencionista

Inscripción (Actual)

62

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • Los Angeles, California, Estados Unidos, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Ann and Robert H. Lurie Children's Hospital of Chicago
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan - Mott Children's Hospital
    • New York
      • New York, New York, Estados Unidos, 10032
        • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27703
        • Duke University
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84113
        • University of Utah - Intermountain Primary Children's Hospital
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Seattle Children's Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 año a 16 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.

  1. Age 18 months to 16 years.

  2. Male or female.

  3. Subject has a native or repaired right ventricular outflow tract.

  4. Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).

  5. Subject has at least one of the following echocardiographic findings:

    1. Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
    2. Moderate or greater pulmonary regurgitation;
    3. Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
  6. Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).

  7. Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.

  8. Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are met:

  1. Subject requires valve replacement in a non-pulmonary position.
  2. Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
  3. Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
  4. Subject has pulmonary atresia and major aortopulmonary collaterals.
  5. Subject has significant peripheral pulmonary artery stenosis.
  6. Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
  7. Subject has active endocarditis or a history of infective endocarditis.
  8. Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
  9. Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
  10. Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
  11. Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
  12. Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
  13. Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
  14. Subject needs emergency cardiac or vascular surgery or intervention.
  15. Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
  16. Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
  17. Subject or parent/legal representative refuses blood transfusions.
  18. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
  19. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Autus Valve Arm

Pulmonary Valve Replacement Surgery with the Autus Valve

Pulmonary valve replacement surgery with the Autus Valve

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Valve Implantation Primary Safety Endpoint
Periodo de tiempo: 30 Days post-valve implantation

Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
30 Days post-valve implantation
Valve Implantation Primary Effectiveness Endpoint
Periodo de tiempo: 6 Months post-valve implantation

Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:

  • A mean RVOT gradient less than or equal to 40 mmHg and
  • Less than moderate pulmonary regurgitation by transthoracic echo and
  • No Autus Valve reintervention except for valve expansion to address prosthesis-patient mismatch.
6 Months post-valve implantation

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Other Safety Outcome - Composite
Periodo de tiempo: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Mortality
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Mortality, including: all cause, cardiac-related, procedure-related and device-related

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve Thrombosis
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Valve thrombosis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Thromboembolism
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Thromboembolism

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Cardiac or Valve Intervention
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Other cardiac or valve intervention (surgical or transcatheter)

30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
Other Safety Outcome - Major Hemorrhage
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Major hemorrhage

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Endocarditis
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Endocarditis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Hemolysis
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Hemolysis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Device Explantation
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Device explantation

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Adverse Events (AE)
Periodo de tiempo: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Adverse events

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve/Stent Fracture
Periodo de tiempo: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.

An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure.

pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
Periodo de tiempo: Immediately Post-Valve Implant Procedure

To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):

  • RV to PA peak systolic pressure gradient <40 mmHg (direct pressure measurement);
  • None or trivial pulmonary regurgitation (assessed via TEE);
  • No paravalvular leak (assessed via TEE).
Immediately Post-Valve Implant Procedure
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
Periodo de tiempo: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Pulmonary Stenosis Grade
Periodo de tiempo: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Right Ventricular Measures
Periodo de tiempo: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Left Ventricular Measures
Periodo de tiempo: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Modified Ross Functional Classification
Periodo de tiempo: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Modified Ross Functional Class as assessed by the Site Investigators

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - PedsQL - Cardiac Module
Periodo de tiempo: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.

The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel.

Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
Other Post-Implant Valve Expansion Safety Outcome - Composite
Periodo de tiempo: 30 days after each post-implant valve expansion procedure

Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:

  • Death;
  • Extracorporeal membrane oxygenation (ECMO) support;
  • Unplanned intervention (surgical or transcatheter);
  • Major hemorrhage
30 days after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
Periodo de tiempo: Immediately after each post-implant valve expansion procedure

To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:

  • RV to aortic systolic pressure ratio: ≤0.5.
  • Peak-to-peak RV to PA systolic pressure gradient: ≤15 mmHg;
  • Peak-to-peak RV to PA systolic pressure gradient: ≥50% reduction (pre vs post valve expansion).
Immediately after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
Periodo de tiempo: 6 months after each post-implant valve expansion procedure

Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:

  • Less than moderate pulmonary regurgitation (PR) by Doppler echocardiography;
  • Transvalvular gradient (assessed by CW Doppler) at 6-months is lower than the pre-expansion gradient.
6 months after each post-implant valve expansion procedure

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de febrero de 2024

Finalización primaria (Actual)

24 de agosto de 2026

Finalización del estudio (Estimado)

5 de febrero de 2036

Fechas de registro del estudio

Enviado por primera vez

23 de julio de 2021

Primero enviado que cumplió con los criterios de control de calidad

12 de agosto de 2021

Publicado por primera vez (Actual)

16 de agosto de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir